Imagine gasping for air while the world moves on around you. For over 260 million people globally living with asthma, and hundreds of millions more battling Chronic Obstructive Pulmonary Disease (COPD), this frightening scenario is a regular reality. Chronic respiratory illnesses are among the leading causes of severe illness and death worldwide, yet the standard method of managing them remains surprisingly reactive.
Patients often wait until they are in the middle of a dangerous breathing crisis before seeking medical attention. This approach strains hospitals, terrifies families, and results in millions of avoidable emergency room visits every year.
In the medical world, diseases like diabetes have long benefited from continuous glucose monitors that track blood sugar fluctuations in real time. Yet, respiratory care has lagged behind, forcing patients to rely on intermittent clinic visits or subjective self-assessments to judge their lung health. The absence of a continuous, objective monitoring system creates a dangerous gap where subtle, early signs of lung deterioration go completely unnoticed until it is too late.
Bringing the Clinic to the Living Room
This massive gap in patient care is exactly what Adrian Ang, the Co-Founder and CEO of Aevice Health, set out to fix. Aevice Health is a Singapore-based medical technology (MedTech) company that spun out of Nanyang Technological University (NTU). Under Ang’s leadership, the company has positioned itself at the cutting edge of remote patient monitoring by transforming the most fundamental tool in respiratory medicine: the stethoscope.
The company’s signature technology is the AeviceMD, an innovative, non-invasive smart wearable stethoscope. Paired with a comprehensive monitoring platform, this small device attaches comfortably to a patient’s chest to continuously track critical biomarkers, such as respiratory rate, heart rate, and distinct lung sounds like wheezing or coughing.
By utilizing advanced, proprietary artificial intelligence (AI) algorithms at the edge, the system processes acoustic data directly on the device. It turns raw biological sounds into clear, longitudinal health insights. This allows healthcare providers to monitor high-risk patients continuously while they go about their daily lives at home.
Turning Childhood Struggles into Impact
For Ang, building a respiratory health empire was not just a clever business opportunity; it was a deeply personal mission. Growing up as an asthmatic child in Singapore, he spent his youth experiencing the terrifying limitations of the disease firsthand. He remembers the sudden panic of breathing attacks, the disruptions to his school life, and the constant, anxious vigilance of his parents, who worried every time he coughed.
Those early experiences left a lasting impression on him. As he grew older and entered the technology space, he realized that the fear and uncertainty his family faced decades ago was still a daily reality for millions of parents and patients today. He saw a clear opportunity to use modern technology to eliminate that constant anxiety.
To turn this vision into reality, Ang joined forces with co-founders Edmund Shao, Dr. Ser Wee, and Dr. Rex Tan (who serves as the company’s Chief Technology Officer). Together, they set out to build a platform that gives chronic respiratory patients complete control over their health, ensuring no family has to suffer through the silent anxiety of unmonitored lung conditions.
Navigating the Demanding MedTech Arena
Transforming a vision into a certified, market-ready medical device is an incredibly complex journey. Unlike standard consumer tech gadgets or software applications, medical devices face a long, strict path of clinical testing, engineering revisions, and tough regulatory checkpoints.
One of the biggest early hurdles for Aevice Health was miniaturizing a highly sensitive acoustic stethoscope into a lightweight, comfortable wearable patch without losing sound quality or accuracy. The device had to be sensitive enough to filter out body movements, clothing friction, and background environmental noise, while still isolating the distinct, subtle sound signatures of a failing lung.
Beyond the engineering challenges, Ang had to guide the company through the expensive and complex world of international healthcare regulation. Building credibility required solid clinical evidence. The company partnered with leading medical institutions to run extensive clinical trials, proving that its automated AI algorithms could identify abnormal lung sounds just as accurately as a trained doctor using a traditional stethoscope.
Earning Major International Recognition
The team’s meticulous approach to clinical validation paved the way for landmark regulatory successes, establishing credibility in local markets before expanding across the globe. Aevice Health achieved its first major commercial breakthrough when the Singapore Health Sciences Authority (HSA) granted official regulatory approval for the AeviceMD platform.
This success in Southeast Asia quickly caught the attention of global healthcare ecosystems. Aevice Health earned a spot in the prestigious Cedars-Sinai Accelerator program in the United States, providing the company with direct access to top-tier clinical mentorship and refining their launch strategy for Western markets.
Shortly after, the company secured official 510(k) Class II clearance from the U.S. Food and Drug Administration (FDA). Crucially, this initial American clearance recognized the platform’s safety and efficacy for both adult and pediatric populations aged three and older, offering a vital remote monitoring solution for vulnerable young asthmatics.
The international tech and medical communities took notice of these combined achievements. The company won the prestigious CES Best of Innovation Award in the digital health category, cementing its status as a rising global leader in medical technology.
| Milestone | Regulatory Body / Organization | Market Impact |
| HSA Approval | Health Sciences Authority (Singapore) | Authorized first-in-market commercial access in Singapore. |
| Initial FDA Clearance | U.S. Food and Drug Administration | Granted Class II clearance for adult and pediatric (ages 3+) remote monitoring. |
| System Expansion | U.S. Food and Drug Administration | Cleared updated software capabilities to deepen remote longitudinal analysis. |
| CES Innovation Award | Consumer Technology Association | Recognized the platform’s breakthrough design in global digital health. |
Redefining the Future of Care
Ang views the success of Aevice Health as part of a much larger shift toward “hospital-at-home” care models. By shifting chronic disease management from reactive emergency room visits to proactive home tracking, the technology helps lower hospital readmission rates, reduces overall healthcare costs, and takes the pressure off busy medical staff.
The long-term goal for AeviceMD is to make it as common and easy to use in households as a standard digital thermometer. Just as diabetes care was transformed by continuous glucose monitoring, Ang is determined to make continuous acoustic lung tracking the global standard for respiratory health. This approach allows doctors to spot early health declines and step in days before a patient experiences a severe, life-threatening asthma attack.
Leading with Purpose and Integrity
As an executive, Ang leads with an organizational philosophy built on professional integrity, deep mutual respect, and a strong commitment to patient outcomes. He actively rejects the old tech mantra of “move fast and break things,” recognizing that in the medical field, engineering mistakes can directly impact human lives. Instead, he promotes a workplace culture centered on rigorous validation, open communication, and shared clinical goals.
Ang works hard to keep his team closely connected to the real-world impact of their work. Whether working with software engineers, acoustic scientists, or regulatory specialists, he reminds his staff that every line of code written and every hardware change made directly helps a child breathe easier or gives a worried parent peace of mind.
This purpose-driven focus has helped the company attract top-tier global investors. To date, Aevice Health has secured a cumulative $9.11 million in capital and grants from major institutional backers, including East Ventures, Denka, and Coronet Ventures, fueling their continuous research and global deployment.
Expanding Care across New Horizons
Looking ahead, Aevice Health is focused on scaling its platform globally and expanding access across Southeast Asia and the United States. The company is actively building on its clinical partnerships, recently launching an at-home pediatric asthma monitoring initiative with Cedars-Sinai Guerin Children’s Hospital in Los Angeles. This program allows doctors to track children’s lung health between clinic visits, keeping kids safe and healthy at home.
At the same time, Ang is directing the company’s expansion into Southeast Asia, where over 48 million people quietly battle chronic respiratory illnesses, often without access to affordable specialist care. By combining accessible, wearable hardware with intelligent AI analytics, Ang and Aevice Health are successfully breaking down geographic boundaries in medicine, ensuring that a healthier, safer recovery is always within arm’s reach for patients around the world.
